Too many candidates fail at the most uncertain stages.
Hit identification, multi-property lead optimization and preclinical ADMET/PK prediction remain costly, uncertain bottlenecks. Data-only AI can struggle when data is sparse, biased or unable to represent the underlying molecular physics.